Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo

Cancer Science

Volumn 99, Issue 9, 2008, Pages 1847-1852

  Stenner, Frank ^a   Liewen, Heike ^a   Zweifel, Martin ^a   Weber, Achim ^a   Tchinda, Joelle ^b   Bode, Beata ^a   Samaras, Panagiotis ^a   Bauer, Stefan ^a   Knuth, Alexander ^a   Renner, Christoph ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BORTEZOMIB; DOCETAXEL; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; SORAFENIB;

ADULT; ANAPLASTIC CARCINOMA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CASE REPORT; DRUG EFFICACY; DRUG TARGETING; DRUG WITHDRAWAL; EXON; GASTROINTESTINAL HEMORRHAGE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KARYOTYPE; LEUKOCYTOSIS; LYMPH NODE METASTASIS; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPHILIA; PRIORITY JOURNAL; THYROID CARCINOMA; TUMOR BIOPSY; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; BORONIC ACIDS; CARCINOMA; CELL LINE, TUMOR; HUMANS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS B-RAF; PYRAZINES; PYRIDINES; THYROID NEOPLASMS;

EID: 50149093848     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00882.x     Document Type: Article

References (19)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA A Cancer J Clin 2007; 57: 43-66.
2. Are C, Shaha AR. Anaplastic thyroid carcinoma: Biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006; 13: 453-64.
3. Garcia-Rostan G, Zhao H, Camp RL et al. Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 2003; 21: 3226-35.
4. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005; 12: 245-62.
5. --targeting to the membrane. Endocr Relat Cancer 2006; 13: 257-69.
6. Nikiforova MN, Nikiforov YE. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn 2008; 8: 83-95.
7. Riesco-Eizaguirre G, Santisteban P. New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy. Endocr Relat Cancer 2007; 14: 957-77.
8. Oka Y, Kobayashi T, Fujita S et al. Establishment of a human anaplastic thyroid cancer cell line secreting granulocyte colony-stimulating factor in response to cytokines. In Vitro Cell Dev Biol 1993; 29A: 537-42.
9. Arizono Y, Yoshikawa H, Naganuma H, Hamada Y, Nakajima Y, Tasaka K. A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents. Br J Cancer 2003; 88: 298-306.
10. Perren A, Schmid S, Locher T et al. BRAF and endocrine tumors: Mutations are frequent in papillary thyroid carcinomas, rare in endocrine tumors of the gastrointestinal tract and not detected in other endocrine tumors. Endocr Relat Cancer 2004; 11: 855-60.
11. Salvatore G, De Falco V, Salerno P et al. BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 2006; 12: 1623-9.
12. Kim S, Yazici YD, Calzada G et al. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther 2007; 6: 1785-92.
13. Mitsiades CS, McMillin D, Kotoula V et al. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in.vitro. J Clin Endocr Metab 2006; 91: 4013-21.
14. O'Neill JP, O'Neill B, Condron C, Walsh M, Bouchier-Hayes D. Anaplastic (undifferentiated) thyroid cancer: Improved insight and therapeutic strategy into a highly aggressive disease. J Laryngol Otol 2005; 119: 585-91.
15. Lorch JH, Thomas TO, Schmoll HJ. Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer. Cancer Res 2007; 67: 727-34.
16. Elliott DD, Sherman SI, Busaidy NL et al. Growth factor receptors expression in anaplastic thyroid carcinoma: Potential markers for therapeutic stratification. Hum Pathol 2008; 39: 15-20.
17. Poulaki V, Mitsiades CS, Kotoula V et al. Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells. Am J Pathol 2002; 161: 643-54.
18. Ishii Y, Waxman S, Germain D. Targeting the ubiquitin-proteasome pathway in cancer therapy. Anticancer Agents Med Chem 2007; 7: 359-65.
19. Zwick E, Bange J, Ullrich A. Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med 2002; 8: 17-23.